Pulmonary arterial hypertension (PAH) patients who fail to respond completely to Adcirca (tadalafil) or Viagra (sildenafil) benefit from Letairis (ambrisentan)…
Articles by Patricia Inácio, PhD
Letairis (ambrisentan) is a safe pulmonary arterial hypertension (PAH) treatment, according to a confirmation of the clinical trial findings that…
An imaging technique called optical coherence tomography (OCT) can effectively determine abnormalities in the lung vasculature of pulmonary arterial hypertension (PAH)…
A small group of stem cells may help repair the lungs of those with pulmonary hypertension (PH), chronic obstructive pulmonary disease…
Letairis (ambrisentan) was the most efficient, robust therapeutic among endothelin receptor antagonists (ERAs) to treat pulmonary arterial hypertension (PAH), according to…
The approved multiple-sclerosis treatment Tecfidera was seen to improve pulmonary arterial hypertension (PAH) and inhibit lung fibrosis in mice by…
A cohort study with Chinese patients identified systemic sclerosis (SSc) as the key underlying disease that significantly worsens the clinical…
A case report of a pulmonary arterial hypertension (PAH) patient who used an implanted hemodynamic monitor illustrates that improvements in pulmonary hemodynamics…
Sildenafil appears to treat pulmonary hypertension (PH) by reducing the recruitment of bone marrow (BM)-derived progenitor cells, cells now being seen as potential…
Researchers found a new mutation in a gene — called eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4) — in members…
Tyvaso (treprostinil sodium), a drug approved for enhancing exercise capacity in patients with pulmonary arterial hypertension (PAH), was reported in a recent…
Pulmonary arterial hypertension (PAH) severity is associated with alterations in the heart’s metabolism, but a recent study showed that Opsumit (macitentan) can reduce…